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Introduction: An adjuvanted pandemic H1N1 influenza (pH1N1) vaccine (Pandemrix®) was reported as highly
immunogenic resulting in seroconversion in 77 to 94% of adults after administration of a single dose. The aim of
the study was to investigate the impact of different anti-rheumatic treatments on antibody response to pH1N1
vaccination in patients with rheumatoid arthritis (RA) and spondylarthropathy (SpA).
Methods: Patients with arthritis (n = 291; mean age 57 years, 64% women) participated. Hemagglutination
inhibition (HI) assay was performed on blood samples drawn before and after a mean (SD) of 8.3 (4) months
following vaccination. A positive immune response i.e. seroconversion was defined as negative prevaccination
serum and postvaccination HI titer ≥40 or a ≥4-fold increase in HI titer. All patients were divided into predefined
groups based on diagnosis (RA or SpA) and ongoing treatment: methotrexate (MTX), anti-tumor necrosis factor
(anti-TNF) as monotherapy, MTX combined with anti-TNF, other biologics (abatacept, rituximab, tocilizumab) and
non-steroidal anti-inflammatory drugs (NSAIDs)/analgesics. Predictors of positive immune response were studied
using logistic regression analysis.
Results: The percentage of patients with positive immune response in the different treatment groups was: 1. RA on
MTX 42%; 2. RA on anti-TNF monotherapy 53%; 3. RA on anti-TNF + MTX 43%; 4. RA on other biologics (abatacept
20%, rituximab 10% and tocilizumab 50%); 5. SpA on anti-TNF monotherapy 76%; 6. SpA on anti-TNF + MTX 47%;
and 7. SpA on NSAIDs/analgesics 59%. RA patients on rituximab had significantly lower (P < 0.001) and SpA on
anti-TNF monotherapy significantly better response rates compared to other treatment groups (P 0.001 to 0.033).
Higher age (P < 0.001) predicted impaired immune response. Antibody titers 3 to 6 months after vaccination was
generally lower compared to those within the first 3 months but no further decrease in titers were observed 6 to
22 months after vaccination.
Conclusions: Rituximab treatment severely reduced antibody response to pH1N1 influenza vaccine. The other
treatment groups showed acceptable antibody responses. Protective antibody titers could be detected up to 22
months after vaccination in the current patient population, with the exception of rituximab treated patients.Introduction
During the 2009 influenza pandemic a mass vaccination
was performed across Europe. In Sweden free vaccination
against pandemic H1N1 (pH1N1) influenza virus was of-
fered to all residents. According to a report from the
Swedish WHO National Influenza Centre published by
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distribution, and reproduction in any mediumthe estimated coverage of H1N1 vaccination in the entire
country was 60%; ranging from 54% to 70% in different
counties [1]. An inactivated, monovalent, split vaccine
(Pandemrix®) containing 3.75 μg hemagglutinin (HA) and
a squalene-based oil-in-water adjuvant system (AS03) was
used [2]. The vaccine was reported as highly immunogenic
resulting in seroconversion in 77% to 94% of adults after
administration of a single dose [2-5]. Usage of the adjuvant
was shown to improve antibody response of the inactivated
vaccine but was associated with more local adverse effects
[3,5,6] compared to unadjuvanted vaccine. Furthermore,ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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following a single dose of adjuvant vaccine was reported in
adult healthy subjects including those 65-years-old and
older [6-8]. In Sweden, all subjects receiving immunosup-
pressive drugs including biological remedies were consid-
ered to be at increased risk of complications from influenza
infection and, therefore, immunization with two doses of
the vaccine preferably administered 21 days apart was rec-
ommended by the Swedish National Board of Health and
Welfare [9]. A number of studies have investigated the in-
fluence of different treatments on the immunogenicity of
seasonal influenza and adjuvanted pH1N1 vaccines in pa-
tients with inflammatory rheumatic diseases with some-
what conflicting results [10-20]. Our group previously
reported antibody response after seasonal influenza vaccine
in rheumatoid arthritis patients (RA) treated with metho-
trexate (MTX) or anti-TNF remedies being as good as that
of healthy controls [21].
We initially conducted an investigator-driven formal
vaccine study with conjugated pneumococcal vaccine
(Prevenar7) in rheumatoid arthritis (RA) and spondylar-
thropathy (SpA) patients including long term antibody de-
velopment [22,23]. The mass vaccination against pH1N1
largely coincided with the Prevenar7 study. Therefore, the
aim of the present study was to investigate immune re-
sponses against an adjuvanted pH1N1 vaccine in relation
to timing (1 to 22 months after vaccination) and dosing
(single/two doses) as well as predictors of positive immune
response in defined cohorts of RA and SpA patients on
different treatments including biologic remedies. We also
aimed to assess tolerability of the pH1N1 vaccine in pa-
tients with RA and SpA treated in clinical practice.
Methods
Consecutive arthritis patients monitored at out-patient
rheumatology units of the Department of Rheumatology,
Skåne University Hospital, Lund and Malmö, Sweden who
were participating in the Prevenar7 vaccination study [22]
were asked to answer a questionnaire regarding pH1N1
influenza vaccination status, including the number of
doses received and tolerability of the vaccine. Information
on seasonal influenza vaccination status in 2009/2010 and,
when appropriate, the winter season 2010/2011 (when
pH1N1 was included in the seasonal vaccine) was also col-
lected. A flowchart of the study population is shown in
Figure 1.
All patients were immunized with a single dose or two
doses of monovalent, split, adjuvanted, pandemic influ-
enza A/H1N1 vaccine (Pandemrix®) containing 3.75 μg
HA and AS03 [2]. Vaccination was performed during the
winter season 2009/2010. In spite of recommendations
some immunosuppressed patients refrained from the sec-
ond dose of vaccine. When two doses were given, the
immunization was performed at least 21 days apart.Antibody response was determined using hemag-
glutination inhibition (HI) assay [24] on stored blood
samples drawn prior to autumn 2009 and after mean
(SD) 8.3 (5) months following vaccination. All sera were
titrated simultaneously and blinded for patients, treat-
ment characteristics and vaccination status.
The seroprotection rate, that is, a percentage of patients
with postvaccination titers ≥40 was calculated. Seroconver-
sion was defined as negative prevaccination serum and
postvaccination HI titer ≥40 or a ≥4-fold increase in HI
titer. Pre- and postvaccination geometric mean titers and
geometric mean fold increase were calculated. The per-
centages of patients who met EU Committee of Human
Medicinal Products (CHMP) licensing criteria for assess-
ment of influenza vaccines were calculated. According to
these criteria sufficient protection against infection in
healthy adults 18 to 60-years old (>60-years-old) is as-
sumed if at least one of three criteria is fulfilled: seropro-
tection rate 70% (60%); seroconversion rate 40% (30%) or
mean increase in geometric mean titer (geometric mean
fold increase) >2.5 (3) [25].
The study was approved by the Regional Ethics Review
Board at Lund University (file numbers 97/2007 and 519/
2009). Informed written consent was obtained from all
subjects before study entry.
Statistical analysis
Non-parametric tests were generally used. Differences
in positive immune response between treatment groups
were calculated using the Chi2 test. Geometric mean
antibody titers (GMT) were calculated using log trans-
formed antibody levels. Possible predictors of positive




Patient selection is outlined in the flow chart in Figure 1.
The Prevenar7 vaccine study cohort consists of 505 pa-
tients with RA or SpA participating in the original study
and 88 additional subsequently included patients treated
with other biologics than anti-TNF remedies. The inclu-
sion criteria for that study were that anti-rheumatic treat-
ment had not been changed for at least four weeks before
the inclusion [22]. Biological remedies were administered
according to daily clinical practice and at least two treat-
ment courses had been given before the study entry.
Treatment with at least one anti-TNF drug before switch-
ing to other biological modalities (abatacept, rituximab or
tocilizumab) was mandatory at our Department when the
study was initiated.
Of all 593 patients, 427 answered the questionnaire re-
garding pH1N1 influenza vaccine. Seventy had refrained
from pH1N1 vaccination while 359 patients acknowledged
Figure 1 Flowchart of the study population.
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vated adjuvant vaccine. Of these, there were 334 with
stored serum samples before and after pH1N1 vaccination.
Since seasonal influenza vaccine for 2010/2011 contained
a pH1N1 virus strain, patients immunized with that vac-
cine were excluded from the analysis if their blood sam-
ples were collected after that vaccination. In total, 291
patients were included in the main analysis. Based on
diagnosis and ongoing anti-rheumatic treatments patients
were stratified into the following groups: 1) RA on MTX
(n = 50); 2) RA on anti-TNF as monotherapy (n = 38); 3)
RA on anti-TNF +MTX (n = 53); 4) RA on other biologics
(abatacept (n = 5), rituximab (n = 10), tocilizumab (n = 2));
5) SpA on anti-TNF as monotherapy (n = 41); 6) SpA on
anti-TNF +MTX (n = 51); and 7) SpA on NSAIDs/analge-
sics (controls, n = 41). Patient characteristics for different
treatment groups are given in Table 1.
Timing after pH1N1 vaccination
Blood samples were drawn prior to and after mean
8.3 months (SD 4); range 1 to 22 months following vac-
cination. During this time period biological treatments
were continued according to clinical practice and
rituximab-treated patients may have received more than
one treatment course. Figure 2 shows the box plots with
postvaccination antibody titers in relation to time
elapsed between vaccination and blood samplings.
Three to six months after vaccination antibody titers
were generally lower compared to those collected within
the first three months but no further decrease in these ti-
ters was observed in patients whose samples were col-
lected >6 months after the vaccination. The time periodbetween vaccination and retrieval of blood samples did
not influence positive antibody response (P = 0.306).
Immune response after pH1N1 vaccination
A positive immune response, that is, seroconversion, was
defined as prevaccination antibody titers <10 and postvacci-
nation HI titer ≥40 or a ≥4-fold increase in HI titer.
Table 2 summarizes prevaccination- and postvaccination
GMT, geometric mean fold increase, number (%) of pa-
tients with prevaccination and postvaccination antibody ti-
ters ≥40 (seroprotection) and positive immune response
(seroconversion) in the entire study population and differ-
ent treatment groups after immunization with a single
dose, two doses, or all immunized patients irrespective of
doses of the pH1N1 vaccine. The percentage of patients
immunized with seasonal influenza vaccine in 2009/2010
is also given. Figure 3 illustrates the proportion (%) of pa-
tients with a positive immune response in different treat-
ment groups stratified according to the number of vaccine
doses administered.Immunization with a single dose or two doses of the vaccine
Of the 291 patients, 123 (42%) received one dose of the
vaccine. Patients treated with rituximab had signifi-
cantly lower postvaccination GMT, lower mean in-
crease in geometric mean titer compared to other
treatment groups and only one patient (25%) with a
positive immune response (seroconversion). Vaccin-
ation with a single dose did not meet any CHMP cri-
teria for protection against infection in rituximab
treated patients as a group. Otherwise, the proportion






























57 (23 to 87) 62.3 (26 to 87) 62.4 (32 to 86) 61.1 (41 to 83) 55.2 (43 to 66) 62.3 (43 to 79) 63.5 (55 to 72) 49.0 (2 to 69) 52.6 (26 to 71) 52.2 (23 to 72)
Gender (% female) 64 78 84 80 86 80 100 37 51 51
Disease duration
(years) mean (range)
16.0 (1 to 55) 12.5 (1 to 41) 21.1 (3 to 46) 18.2 (2 to 48) 12.4 (6 to 24) 22.3 (5 to 55) 21.5 (15 to 28) 16.6 (1 to 36) 13.1 (1 to 42) 14.3 (1 to 37)
RF positive (%) 43 76 87 76 100 80 100 ——— ——— ——
Anti-CCP positive (%) 43 82 74 83 80 80 50 ———— ——— ……
HLA-B27 positve (%) 22.3 ——— ———— ——— ———— ————— ———— 56 28 68















Figure 2 Box plots with postvaccination antibody titers in relation to the time between vaccination and drawing of blood samples.
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ceiving a single dose of vaccine was similar in all treat-
ment groups.
Of the 291 patients, 168 (58%) received two doses of the
vaccine. Compared to a single dose, immunization with
two doses of the vaccine overall resulted in more patients
with a positive immune response in all treatment groups
except for RA patients on MTX and RA patients on ritux-
imab. The proportion of MTX-treated RA patients with
positive immune response after a single dose of the vac-
cine and after two doses were 45% and 41%, respectively.
None of six RA patients on rituximab immunized with
two doses had a positive immune response.All immunized patients (single and two doses together)
The percentage of patients with a positive immune re-
sponse in the different treatment groups was: 1) RA on
MTX, 42%; 2) RA on anti-TNF monotherapy, 53%; 3) RA
on anti-TNF +MTX, 43%; 4) RA on other biologics (aba-
tacept 20%, rituximab 10% and tocilizumab 50%); 5) SpA
on anti-TNF monotherapy, 76%; 6) SpA on anti-TNF +
MTX, 47%; and 7) SpA on NSAIDs/analgesics, 59%. The
entire study population, single or two vaccine doses,
showed a similar pattern, with SpA patients on anti-TNF
as monotherapy having a significantly larger responder
proportion compared to the other treatment groupsexcept for SpA on NSAIDs/analgesics (Chi2/Fisher’s exact
test; P between <0.001 and 0.033).
RA patients treated with rituximab (n = 10) showed a
significantly impaired antibody response compared to all
other treatment groups with only one patient showing a
positive immune response.
Abatacept treated patients (n = 5) as a group showed a
decreased antibody response compared to the other
treatment groups. The limited number of patients pre-
cluded further analysis.
Only two RA patients treated with tocilizumab partic-
ipated in the study. However, both patients were able to
gain high postvaccination antibody titers comparable
with those of SpA patients on anti-TNF as monotherapy
or SpA patients receiving NSAIDs/analgesics.
Immune response in relation to age
Table 3 and Figure 4 summarize immune response in
the entire study population and different treatment
groups stratified for age, that is, subjects 18- to 60-years
old (n = 142) and those ≥60-years old (n = 149). Regard-
less of age, rituximab treated patients as a group did not
fulfill any CHMP serologic criteria for response. Fur-
thermore, no abatacept treated patients <60 years met
any of CHMP criteria. All other treatment groups ful-
filled at least one serological criterion indicating protec-
tion against pH1N1 infection.





























Patients immunized with a single dose of the vaccine (number = 123)












5.6 (3.6 to 8.8) 5 (2.1 to 12.2) 2.8 (1.6 to 5.1) 2.8 (1.4 to 5.4) 2.5 (0.3 to 18.4) 2 (0.4 to 9.5) — 4.7 (2.1 to 10.5) 2.3 (1.1 to 4.8) 5.2 (3.2 to 8.4)




8 (7%) 0 2 (11%) 0 1 (33%) 0 — 1 (8%) 1 (6%) 3 (9%)














22 33 44 20 0 0 —— 0 11 24
aNo significant differences between treatment groups.
Patients immunized with two doses of the vaccine (number = 168)
Number of patients 168 32 20 38 2 6 2 28 33 7
GMT prevaccination
mean (95% CI)
9.2 (8.2 to 10.4) 9.8 (7.1 to 13.4) 8.7 (6.3 to 12.1) 6.8 (5.6 to 8.3) 20 (3.3 to 121) 7.9 (3.7 to 16.8) 28 (0.3 to 2312) 9.5 (7.1 to 12.7) 10.7 (8.1 to 14.1) 12.2 (5 to 29.5)
GMT postvaccination
mean (95% CI)
50 (40.4 to 61.8) 40 (23.9 to 67.5) 72 (33 to 159) 34 (21.5 to 54) 33.6 (6.4 to 176) 8.9 (3.8 to 21) 113 102.5 (69 to 153) 48.3 (32 to 73.4) 97.5 (33 to 291)
Geometric mean fold
increase (95% CI)
5.4 (4.3 to 6.8) 4.1 (2.5 to 6.7) 8.3 (3.7 to 18.5) 5 (3–8.3) 2 1.1 (0.5 to 2.6) 4 (0—) 11 (6.7 to 17.3) 4.5 (2.6 to 7.8) 8 (1.5 tp\o 43.6)
N (% ) of patients
with prevaccination
titer ≥40















Table 2 Immune response following vaccination with single dose, two doses or irrespective of number of doses (Continued)
N (% ) of patients
with postvaccination
titer ≥40
106 (63%) 16 (50%) 14 (70%) 18 (48%) 1 (50%) 1 (17%) 2 (100%) 24 (86%) 24 (73%) 6 (86%)








46% 59% 40% 51% 100 50 100 32 36 43
aP = 0.003 compared to RA on MTX; P = 0.033 compared to RA on anti-TNF monotherapy; P = 0.001 compared to RA on anti-TNF +MTX; P = 0.005 compared to SpA on antiTNF + MTX; bP = 0.039 versus
RA on anti-TNF monotherapy (Chi2 test).
All vaccinated patients regardless of number of doses (number = 291)












4.6 (3.9 to 5-5) 4.4 (2.9 to 6.9) 5 (3 to 8.3) 4.2 (2.8 to 6.3) 2.3 (0.9 to 5.9) 1.4 (0.8 to 2.6) 4 8.3 (5.5 to 12.5) 3.6 (2.3 to 5.5) 5.6 (3.6 to 8.8)
N (% ) of patients
with prevaccination
titer ≥40
25 (9%) 6 (12%) 3 (8%) 1 (2%) 2 (40%) 0 1 (50%) 3 (7%) 4 (8%) 5 (12%)




167 (57%) 25 (50%) 22 (58%) 24 (45%) 2 (40%) 2 (20%) 2 (100%) 31 (76%) 33 (63%) 27 (66%)








104 (36%) 50% 42% 42% 40% 30% 100% 22% 28% 27%
aP = 0.001 compared to RA on MTX; P = 0.033 compared to RA on anti-TNF as monotherapy; P = 0.002 compared to RA on anti-TNF + MTX; P = 0.011 compared to RA on abatacept; P < 0.001 compared
to RA on rituximab; P = 0.006 compared to SpA on anti-TNF + MTX; bP = 0.05 compared to RA on rituximab; cP = 0.013 compared to RA on rituximab; P = 0.033 compared to SpA on dP = 0.046
compared to RA on rituximab (Chi2 test/Fisher’s exact test).
Positive immune response, that is seroconversion, was defined as prevaccination titers <10 and postvaccination HI titers ≥40 or a ≥4-fold increase in HI titers. Percentages of patients vaccinated against seasonal
influenza during the 2009/2010 winter season are also given. CI, confidence interval; GMT, geometricial mean antibody titer; HI, hemagglutination inhibition; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory















Figure 3 Proportion (%) of patients with positive immune response, that is seroconversion (defined as prevaccination titers <10 and
postvaccination HI titers ≥40 or a ≥4-fold increase in HI titers), in different treatment groups stratified according to the number of
doses of vaccine. HI, hemagglutination inhibition.
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regression analysis (all patients)
Higher age was associated with an impaired positive
antibody response (P < 0.001). Compared to RA more
patients with SpA showed a positive immune response
(P = 0.004). Ongoing MTX and rituximab were associ-
ated with an impaired immune response (P = 0.004 and
P = 0.033, respectively). Prevaccination antibody titers
were inversely associated with a positive immune re-
sponse (P = 0.011). Smokers had a significantly lower
antibody response (P = 0.020). Neither time period be-
tween vaccination and retrieval of blood samples nor
immunization against seasonal influenza 2009/2010 influ-
enced immune response to pH1N1 vaccine significantly.
Multivariate logistic regression analysis (all patients)
The results of multivatiate logistic regression analysis in-
cluding the time period between vaccination and collect-
ing of blood samples are shown in Table 4. Higher age,
higher prevaccination antibody titers and current smok-
ing remained significant predictors of impaired immune
response. The time between vaccination and retrieval of
blood samples (months) did not have a significant im-
pact on antibody response. The difference in response
between patients with RA and SpA was not significant
after adjustment in the regression model (Table 4).
Patients with negative prevaccination antibody levels
All patients with prevaccination antibody levels <10 were
considered to have negative prevaccination serum, that is,
not previously exposed to pH1N1 antigen (neoantigen).
The percentage of patients with negative prevaccination
serum in different treatment groups were: 1) RA on MTX,
19%; 2) RA on anti-TNF monotherapy, 16%; 3) RA onanti-TNF +MTX, 24%; 4) RA on other biologics (aba-
tacept 1%, rituximab 4% and tocilizumab 0%); 5) SpA
on anti-TNF monotherapy, 13%; 6) SpA on anti-TNF +
MTX, 14%; and 7) SpA on NSAIDs/analgesics, 13%.
Higher age, RA diagnosis and current smoking were
associated with impaired antibody response (P < 0.001,
P < 0.001 and P = 0.007, respectively) (univariate re-
gression analysis). After adjustment in the multivariate
logistic regression model, higher age remained a nega-
tive predictor of positive antibody response (P < 0.001)
and current smoking showed a trend to a negative im-
pact (P = 0.06). Corresponding to the results for all
patients, differences in positive antibody response be-
tween SpA and RA were not significant. The time be-
tween vaccination and retrieval of blood samples
(months) had no significant impact on antibody re-
sponse in patients with negative prevaccination anti-
body levels.Safety of the vaccine
The vaccine was well tolerated and caused mostly mild
to moderate side effects. Of 334 patients, 53 reported
local pain and tenderness around the injection site, 41
patients had fever for a few days, and ten had influenza-
like symptoms with muscle pain, headache and fatigue.
A few patients experienced dizziness and upper airways
infection. One subject developed pneumonia requiring
treatment with antibiotics but not hospitalization.
Of 291 patients, 24 (8.2%) reported that vaccination
influenced their rheumatic disease. The majority of these
patients described more pain in their joints without ob-
jectively confirmed synovitis and six others reported in-
creased morning stiffness and fatigue.


























































51% 64% 56% 43% 50% 43% 100% 50% 56% 27%
18-60 years
















16 (11%) 1 (7%) 1 (9%) 0 2(67%) 0 1 (100%) 3 (10%) 3( 9%) 5 (19%)



























20% 14% 9% 39% 33% 0 100% 13% 14% 27%
Positive immune response, that is seroconversion, was defined as prevaccination titers <10 and postvaccination HI titers ≥40 or a ≥4-fold increase in HI titers. CI, confidence interval; GMT, geometricial mean antibody















Figure 4 The percentage of patients with a positive immune response, that is seroconversion, (defined as prevaccination titers <10
and postvaccination HI titers ≥40 or a ≥4-fold increase in HI titers) following vaccination against H1N1 influenza stratified according
to age (18 to 60 years and ≥ 60 years). The dashed lines denote seroconversion levels in healthy individuals when sufficient protection against
infection is assumed (EU Committee of Human Medicinal Production criteria; CHMP). HI, hemagglutination inhibition.
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seasons 2009/2010 and 2010/2011
In total, 113 patients (34%) reported being immunized with
seasonal influenza vaccine during the same winter season
(2009/2010). Immunization with seasonal influenza vaccine
(2009/2010) did not influence antibody response after
pH1N1 vaccine significantly (univariate analysis). Forty
three patients reported being vaccinated against seasonal
influenza 2010/2011 at the sampling time and were, there-




Time between vaccination and retrieving of blood samples (months)
Current smoking (yes/no)
Pre-vaccination antibody titers
Analysis was performed using a multivariate logistic regression model. CI, confidenc
* Seroconversion is defined as prevaccination titres <10 and postvaccination HI ≥4033 (77%) were women and 26 (61%) had RA. Mean time
(range) between vaccination against pH1N1 influenza and
sampling was 11(9 to 15) months. In total, 36 (84%) had
protective antibody titers after vaccination and 34 (79%)
had a positive antibody response (seroconversion).
Patients who refrained from vaccination
In total, 70 patients refrained from the Pandemrix® vac-
cination. Of these, 46 (66%) were women and 43 (60%)
had RA. Mean age and mean disease duration (range) inion)*







e interval; HI, hemagglutination inhibition; OR, odds ratio.
or a ≥4-fold increase in HI titers.
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The distribution of these patients in different treatment
groups (1 to 6) were: 1. 11%, 2. 20%, 3. 17%, 4. 3%, 9%, 1%;
4. 17% 5. 11% and 6.10%. Only five of these patients (7%)
were vaccinated against seasonal influenza 2009/2010.
Blood samples were available in 26 of these patients.
In total, three patients (11%) increased in antibody titers
and reached protective levels in spite of not being vacci-
nated against pH1N1 influenza in sera collected after
the vaccination campaign. Demographic characteristics
did not differ significantly between patients who received
vaccine against pH1N1 influenza and those refraining
from vaccination.
Discussion
We report on the influence of modern anti-rheumatic
treatment on long-term immune response following vac-
cination with inactivated, monovalent, adjuvanted vac-
cine against pH1N1 influenza virus performed during
the winter season 2009/2010 in patients with established
arthritis. More than eight months after vaccination, the
positive immune response in SpA patients on anti-TNF
as monotherapy was still as good as that reported for
healthy adults three to four weeks after vaccination [3].
Arthritis patients on MTX or anti-TNF combined with
MTX had a lower immune response compared to re-
sponses reported for healthy adults but still met CHMP
serologic criteria for protection against infection. An-
other important finding is that the antibody levels
remained protective for a substantial time after pH1N1
vaccination without a clear diminishing pattern within
the current follow up time frame.
Ongoing CD20 depleting treatment in RA using rituxi-
mab is associated with severely diminished immune re-
sponse regardless of the patient’s age.
Interestingly, in RA patients on MTX treatment we did
not observe an increased percentage of responders in
those who received two vaccine doses compared to those
who received one dose. MTX-treated patients younger
than 60 years showed a better antibody response, with
64% of these patients having a positive immune response
compared to 33% of these patients ≥60 years. This differ-
ence probably reflects the age-associated decline in im-
munity affecting both T- and B-cells (immunosenescence)
[26,27]. Although immune responses in MTX-treated pa-
tients were lower than those reported for healthy adults,
patients on MTX as a group meet at least one criterion re-
quired for protection according to CHMP [2-6,25]. Adler
et al. found MTX to be a significant predictor of dimin-
ished immune response following pH1N1 influenza vac-
cine in patients with different inflammatory rheumatic
diseases and none of the MTX-treated patients fulfilled
CHMP criteria six months after vaccination. Apart from
differences in the study population, patients participatingin that study were treated with higher MTX doses given ex-
clusively subcutaneously which might explain the diverging
results [10]. In another study, MTX along with other
disease-modifying anti-rheumatic drugs (DMARDs) was
identified as a predictor of diminished response after
immunization with Pandemrix® vaccine [13]. Elkayam et al.
reported lower antibody response after a single dose of an-
other adjuvanted H1N1 vaccine in patients with different
rheumatic diseases compared to healthy controls but MTX
was not associated with impaired immune response [14].
RA patients receiving anti-TNF treatment in the present
study showed a lower antibody response compared to that
of healthy adults (two to five) after a single dose of the
vaccine, but boosting with an additional dose improved
antibody response which is in accordance with results
from the study of Gabay et al. [13]. Interestingly, antibody
response was not significantly more impaired in RA pa-
tients treated with anti-TNF in combination with MTX
compared to anti-TNF as monotherapy. More than nine
months after immunization, RA patients on anti-TNF as a
group regardless of age still met at least one criterion for
protection according to CHMP. Also, anti-TNF treatment
was not identified as a significant predictor of impaired
antibody response in regression analysis.
The proportion of patients with positive immune re-
sponse (seroconversion) among SpA patients on anti-
TNF as monotherapy was as good as that reported in
healthy controls after two doses of vaccine, both in pa-
tients <60 years old and those older than 60 years [2-5]. A
second dose of the vaccine had a significant boosting ef-
fect in these patients. When anti-TNF treatment was given
in combination with MTX the antibody response was sig-
nificantly lower. The differences between the effect of
anti-TNF on immune response in RA and SpA patients
are in line with previously reported data [10]. Patients with
SpA were on average younger than RA patients which
could at least partly explain these differences. Since RA
patients in general tended to have a lower immune re-
sponse, the impact of the immunological disturbance as a
part of RA disease could not be ruled out.
Our findings are quite different from those reported
by Franco et al. in which SpA patients treated with
infliximab or adalimumab had a diminished antibody
response whereas RA patients on anti-TNF treatment
had as good an immune response as healthy controls
[11]. Patients participating in that study were immu-
nized with a single dose of non-adjuvanted pH1N1 vac-
cine containing 15 μg HA. The usage of adjuvant and a
booster dose of vaccine could explain the enhanced im-
mune response among patients on anti-TNF treatment
in our study. Our results are more in line with a Japa-
nese study in which RA patients on anti-TNF treatment
tended to have a lower antibody response compared to
patients not receiving anti-TNF treatment [12].
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http://arthritis-research.com/content/16/1/R2A recent report in children with juvenile idiopathic
arthritis (JIA) vaccinated against pandemic influenza
showed that the antibody response overall was lower in
patients with JIA, but neither MTX nor anti-TNF rem-
edies affected the immune response significantly [15].
Among children with different rheumatic diseases only
treatment with glucocorticoids was identified as a pre-
dictor of diminished antibody response [16].
Rituximab-treated patients immunized after several
treatment courses showed somewhat lower pre-existing
antibody levels compared to the other treatment groups.
However, the ability of rituximab-treated patients to in-
duce an antibody response was significantly hampered
compared to other treatment groups reflected by lower
postvaccination geometric mean titers (GML), seroprotec-
tion rate and seroconversion rate. These results are in
line with previously reported data following vaccination
against both seasonal and pH1N1 influenza [13,17,18].
B-cells require presentation of a protein antigen (included
in the pH1N1 vaccine) to naïve T-cells for differentiation
into antigen specific immunoglobulin (Ig) producing
plasma cells [28]. Rituximab causes a shortage of mature
B-cells with secondary diminished differentiated plasma
cells and this may explain the decreased antibody response.
The number of abatacept-treated patients in the present
study was limited but the seroconversion rate among this
group was lower compared to other treatment groups with
the exception of RA patients on rituximab. Abatacept-
treated patients had significantly higher prevaccination anti-
body levels and seroconversion may underestimate whether
there were true responses. However, a recently published
study reported severely reduced immune response to pan-
demic influenza vaccination in 11 RA patients treated with
abatacept [19]. Further studies investigating the impact of
rituximab and abatacept on the immunogenicity of neoanti-
gens are needed.
Only two tocilizumab treated patients participated in
the present study. Both were immunized with two doses
of the vaccine and responded with a satisfactory immune
response well in line with a recent report of satisfactory
antibody response in RA patients on tocilizumab [20].
Antibody response following vaccination diminishes
during aging (immunosenescence). This is explained by
changes in the immune system affecting both B- and T-
cells [26]. A rapid decline of protective antibody levels
four months after seasonal influenza vaccination has also
been reported in the elderly [27]. Patients younger than
60 years who participated in the present study had sig-
nificantly better antibody responses compared to those
older than 60 years. Higher age was identified as a pre-
dictor of impaired antibody response in the univariate
analysis and also remained after adjustment for diagno-
sis, disease duration, smoking status and prevaccination
antibody titers in the multivariate regression analysis.Current smoking was associated with diminished antibody
response. We found smoking to be associated with an im-
paired antibody response following pneumococcal vaccin-
ation in the same patient cohort [29]. Our results are in
line with a recent study in which smoking was negatively
associated with persistence of seroprotection 12 months
after immunizaion against pH1N1 influenza using the
AS03 adjuvanted vaccine in HIV-infected adults [30].
Patients immunized against seasonal influenza during
2010/2011 showed higher seroprotection and serocon-
version rates compared to other patients. This indicates
that seasonal influenza vaccine containing pH1N1 virus
strain was able to boost immune response in these im-
munosuppressed arthritis patients.
During the 2009 influenza pandemic in Sweden vac-
cination was performed using vaccine containing the
AS03 system [2]. This adjuvant has been shown to en-
hance the antibody response to inactivated pH1N1 vac-
cine in both younger and older adults [5]. The impact of
the adjuvant on the immunogenicity of the vaccine may
at least partly explain the diverging results in the present
study compared to those reported after vaccination with
unadjuvanted influenza vaccine [3,11,19,30].
Strengths of the present study are that the analyses were
blinded for demographic and treatment data and the stan-
dardized blood sampling as part of a vaccination study in
arthritis patients treated in clinical practice. Limitations
include possible recall bias of vaccination status (retro-
spectively collected information) and the fact that anti-
body response is a surrogate marker of protection. The
numbers of patients treated with biological remedies other
than TNF-antagonists and those in different groups after
categorization for diagnosis, treatment or doses of pH1N1
vaccine was too limited to allow multiple comparisons be-
tween groups. Furthermore, the considerable proportion
of patients with pre-existing antibody levels limits the abil-
ity to detect a positive response. However, analysis includ-
ing patients with negative prevaccination levels (that is,
titers <10) for whom pH1N1 represents a neoantigen did
not show diverging results compared to the entire study
population. Our data would suggest that approximately
10% (3/26) of non-vaccinated patients with negative pre-
vaccination levels who reached protective levels of pH1N1
were exposed to pH1N1 antigen during the current obser-
vation period.
The variable time periods of postvaccination samples
collection limits comparison with other studies asses-
sing antibody response four to six weeks after vaccin-
ation. On the other hand, we demonstrated persistence
of protective antibody titers several months after
immunization.
In spite of these weaknesses, our results reflect the
cross-sectional picture of arthritis patients met in daily
rheumatologic clinical practice.
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http://arthritis-research.com/content/16/1/R2Immunosuppressed patients with arthritis are recom-
mended yearly influenza vaccination but antibody re-
sponse following vaccination is not routinely measured.
Results from the present study confirm that the majority
of these patients (except those on rituximab) would reach
sufficient serological immunity and are expected to be
protected against the infection. For clinicians taking care
of these high risk patients, our results may be used as a
support to recommend influenza vaccination.
Conclusions
Overall, our data support that vaccination yields sero-
logical indications of longstanding protection against
pH1N1 infection in a large proportion of arthritis patients.
Protective antibody titers could be detected for up to 22
months after vaccination in the current patient popula-
tion, with the exception of rituximab- (and possibly
abatacept-) treated patients.
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